Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 13/20 | 0.37 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.37 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ABCB4 | P21439 | 1/20 | 0.37 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.37 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17216124 | 1.00 | LPAR1 (0.37) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL28385967 | 0.92 | LPAR1 (0.38) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL17215847 | 0.91 | LPAR1 (0.34) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL17215633 | 0.90 | LPAR1 (0.33) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL17215634 | 0.90 | LPAR1 (0.33) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL17215342 | 0.90 | LPAR1 (0.37) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL17215351 | 0.90 | LPAR1 (0.37) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL17215358 | 0.89 | LPAR1 (0.47) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL17215466 | 0.89 | OPRM1 (0.43) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL17215469 | 0.89 | OPRM1 (0.43) | LPAR1ABCC3ABCC4ABCB11CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3360869-B1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND USEFUL FOR THE TREATMENT OF DISEASES CAUSED BY LPA. | UBE INDUSTRIES (JP) | 2020-07-29 | — | — | EP | disclosed |
| EP-3162801-B1 | SALT OF HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES (JP) | 2020-07-22 | — | — | EP | disclosed |
| US-10597375-B2 | Halogen-substituted heterocyclic compound | UBE INDUSTRIES, LTD. (JP) | 2020-03-24 | — | — | US | disclosed |
| US-10597375-B2 | Halogen-substituted heterocyclic compound | UBE INDUSTRIES, LTD. (JP) | 2020-03-24 | — | — | US | disclosed |
| US-20180360803-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF NASH | UBE INDUSTRIES, LTD. (JP) | 2018-12-20 | — | — | US | disclosed |
| EP-3378491-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF NASH | UBE Industries, Ltd. (JP) | 2018-09-26 | — | — | EP | disclosed |
| US-20180258062-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2018-09-13 | — | — | US | disclosed |
| US-10023554-B2 | Halogen-substituted heterocyclic compound salt | UBE INDUSTRIES, LTD. (JP) | 2018-07-17 | — | — | US | disclosed |
| US-10000463-B2 | Halogen-substituted heterocyclic compound | UBE INDUSTRIES, LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-10000463-B2 | Halogen-substituted heterocyclic compound | UBE INDUSTRIES, LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| EP-2940013-B1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES (JP) | 2018-02-21 | — | — | EP | disclosed |
| US-20170158663-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND SALT | UBE INDUSTRIES, LTD. (JP) | 2017-06-08 | — | — | US | disclosed |
| EP-3162801-A1 | SALT OF HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE Industries, Ltd. (JP) | 2017-05-03 | — | — | EP | disclosed |
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
| EP-2940013-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE Industries, Ltd. (JP) | 2015-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158663-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND SALT | LPAR1, LPAR3, LPAR2 | LPAR1 1/4885ABCC3 2344/4885ABCC4 2242/4885 |
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | LPAR3, LPAR1, LPAR2 | LPAR1 2/4885ABCC3 607/4885ABCC4 1383/4885 |
| US-10000463-B2 | Halogen-substituted heterocyclic compound | LPAR1, LPAR4, LPAR2 | LPAR1 1/4885ABCC3 1823/4885ABCC4 1635/4885 |
| US-20180360803-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF NASH | LIPC, LPAR1, LPAR3 | LPAR1 2/4885ABCC3 556/4885ABCC4 932/4885 |
| US-20180258062-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | LPAR3, LPAR1, LPAR2 | LPAR1 2/4885ABCC3 607/4885ABCC4 1383/4885 |
| US-10023554-B2 | Halogen-substituted heterocyclic compound salt | LPAR1, LPAR2, LPAR3 | LPAR1 1/4885ABCC3 2353/4885ABCC4 2230/4885 |
| US-10597375-B2 | Halogen-substituted heterocyclic compound | LPAR3, LPAR1, LPAR2 | LPAR1 2/4885ABCC3 607/4885ABCC4 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.